We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Dr. Reddy's (RDY) to Report Q4 Earnings: What's in Store?
Read MoreHide Full Article
Dr. Reddy’s Laboratories Ltd. (RDY - Free Report) is scheduled to report fourth-quarter fiscal 2019 results, before the market opens, on May 17.
The company’s shares have increased 6.1% year to date compared with the industry’s growth of 2.0%.
Let’s see how things are shaping up for this announcement.
Factors in Play
Dr. Reddy’s North American generics unit is witnessing pricing pressures since the last few quarters, due to enhanced channel consolidation and increased competitive pressure on sales of some of the key generic products. We do not expect to see any improvement in this negative trend in the upcoming quarterly results.
The U.S. generics industry is facing significant competitive and pricing pressures. The ongoing consolidation of customers in the industry has led to increasing price erosion and decreasing volumes. The consolidation in the industry has increased the ability to negotiate lower prices for generic drugs. A sharp decline in generic drug prices is proving to be a major challenge for generic drug makers and distributors.
However, generics sales should continue to improve in the Emerging Markets and India units. Moreover, revenues are expected to continue to rise in the Pharmaceutical Services & Active Ingredients (“PSAI”) segment. Sales declined in the Proprietary Products and Others segments in the fiscal third quarter and it remains to be seen if the metric improves in the to-be-reported quarter.
As of Dec 31, 2018, Dr. Reddy’s had 103 generic filings (100 abbreviated New Drug Applications [ANDAs] and three new drug applications) that are pending FDA approval. Of these ANDAs, 59 were Para IV filings and 33 have first-to-file status. We expect to get more updates on the company’s NDA filings during the fourth-quarter conference call.
Dr. Reddy’s currently carries a Zacks Rank #3 (Hold).
Dr. Reddy's Laboratories Ltd Price and EPS Surprise
Here are some stocks you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat this quarter. According to the Zacks model, a company with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 has a good chance of beating estimates if it also has a positive Earnings ESP. Zacks Rank #4 or #5 (Sell-rated) stocks are best avoided.
LogicBio Therapeutics, Inc. has an Earnings ESP of +25.84% and a Zacks Rank #3.
Biogen, Inc. (BIIB - Free Report) has an Earnings ESP of +0.15% and a Zacks Rank #2.
Zacks' Top 10 Stocks for 2019
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-holds for the year?
Who wouldn't? Our annual Top 10s have beaten the market with amazing regularity. In 2018, while the market dropped -5.2%, the portfolio scored well into double-digits overall with individual stocks rising as high as +61.5%. And from 2012-2017, while the market boomed +126.3, Zacks' Top 10s reached an even more sensational +181.9%.
Image: Bigstock
Dr. Reddy's (RDY) to Report Q4 Earnings: What's in Store?
Dr. Reddy’s Laboratories Ltd. (RDY - Free Report) is scheduled to report fourth-quarter fiscal 2019 results, before the market opens, on May 17.
The company’s shares have increased 6.1% year to date compared with the industry’s growth of 2.0%.
Let’s see how things are shaping up for this announcement.
Factors in Play
Dr. Reddy’s North American generics unit is witnessing pricing pressures since the last few quarters, due to enhanced channel consolidation and increased competitive pressure on sales of some of the key generic products. We do not expect to see any improvement in this negative trend in the upcoming quarterly results.
The U.S. generics industry is facing significant competitive and pricing pressures. The ongoing consolidation of customers in the industry has led to increasing price erosion and decreasing volumes. The consolidation in the industry has increased the ability to negotiate lower prices for generic drugs. A sharp decline in generic drug prices is proving to be a major challenge for generic drug makers and distributors.
However, generics sales should continue to improve in the Emerging Markets and India units. Moreover, revenues are expected to continue to rise in the Pharmaceutical Services & Active Ingredients (“PSAI”) segment. Sales declined in the Proprietary Products and Others segments in the fiscal third quarter and it remains to be seen if the metric improves in the to-be-reported quarter.
As of Dec 31, 2018, Dr. Reddy’s had 103 generic filings (100 abbreviated New Drug Applications [ANDAs] and three new drug applications) that are pending FDA approval. Of these ANDAs, 59 were Para IV filings and 33 have first-to-file status. We expect to get more updates on the company’s NDA filings during the fourth-quarter conference call.
Dr. Reddy’s currently carries a Zacks Rank #3 (Hold).
Dr. Reddy's Laboratories Ltd Price and EPS Surprise
Dr. Reddy's Laboratories Ltd price-eps-surprise | Dr. Reddy's Laboratories Ltd Quote
Stocks That Warrant a Look
Here are some stocks you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat this quarter. According to the Zacks model, a company with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 has a good chance of beating estimates if it also has a positive Earnings ESP. Zacks Rank #4 or #5 (Sell-rated) stocks are best avoided.
CannTrust Holdings Inc. is scheduled to release results on May 14. The company has an Earnings ESP of +6.25% and a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank stocks here.
LogicBio Therapeutics, Inc. has an Earnings ESP of +25.84% and a Zacks Rank #3.
Biogen, Inc. (BIIB - Free Report) has an Earnings ESP of +0.15% and a Zacks Rank #2.
Zacks' Top 10 Stocks for 2019
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-holds for the year?
Who wouldn't? Our annual Top 10s have beaten the market with amazing regularity. In 2018, while the market dropped -5.2%, the portfolio scored well into double-digits overall with individual stocks rising as high as +61.5%. And from 2012-2017, while the market boomed +126.3, Zacks' Top 10s reached an even more sensational +181.9%.
See Latest Stocks Today >>